ERYMAX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Erymax, and what generic alternatives are available?
Erymax is a drug marketed by Merz Pharms and is included in one NDA.
The generic ingredient in ERYMAX is erythromycin. There are one hundred and three drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the erythromycin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Erymax
A generic version of ERYMAX was approved as erythromycin by TORRENT on July 6th, 2020.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ERYMAX?
- What are the global sales for ERYMAX?
- What is Average Wholesale Price for ERYMAX?
Summary for ERYMAX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 103 |
| Patent Applications: | 4,170 |
| DailyMed Link: | ERYMAX at DailyMed |
US Patents and Regulatory Information for ERYMAX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merz Pharms | ERYMAX | erythromycin | SOLUTION;TOPICAL | 062508-002 | Jul 11, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
